Summary
Piroxantrone is one of the anthrapyrazoles developed in an effort to combine the broad antitumor activity of the anthracyclines with decreased myocardial toxicity. It has shown activity in metastatic melanoma during phase I trials. The Southwest Oncology Group (SWOG) conducted a phase II trial in disseminated malignant melanoma with piroxantrone administered at 150 mg/m2 intravenously over 1 h every 21 days, based upon the phase I experience. Forty-six eligible patients were registered to the trial and 44 were evaluable for response. Two partial responses, Wayne of 6 and 9 months duration were observed for an overall response rate of 5% (95% confidence interval 1%–15%). Thirty-six of 46 eligible patients have died with an estimated median survival of 5 months (95% confidence interval 3–8 months). Toxicities were tolerable with granulocytopenia being the predominant toxicity. Based upon the observed response rate, it is concluded that piroxantrone administered at this dose and schedule has detectable but minimal activity, and does not warrant further investigation in this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balch CM, Houghton AN, Peters AN: Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA., Lippincott, 1993, pp 1612–1661
Legha SS: Current therapy of malignant melanoma. Semin Oncol 16: 34–44, 1989
McClay EF, Mastrangello MJ: Systemic chemotherapy for melanoma. Semin Oncol 15: 569–577, 1988
Legha SS, Buzaid AC: Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol (suppl 9) 20: 27–32, 1993
Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338–1343, 1992
Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks R, Auclerc G, Soubrane C, Banzet P, Weil M: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon-alfa-2a for metastatic melanoma. J Clin Oncol 11: 2173–2180, 1993
Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon-alpha-2b to dacarbazine in the treatment of patients with metastatic melanoma. J Clin Oncol 9: 1403–1408, 1991
Atkins MB, O’Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, Eckardt JR, Pereira C, Aronson F: Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12: 1553–1560, 1994
Showalter HDH, Johnson JL, Werbel LM, Leopold WR, Jackson RC, Elslager EF: 3-[(Aminoalkyl)amino]-substituted anthral [1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents, synthesis and biological evaluation. J Med Chem 27: 253–255, 1984
Hacker MP, Newman RA, Fagan MS: The fetal mouse heart: a potential model for anthracycline-induced cardiotoxicity. Drugs Exp Clin Res 9: 39–44, 1983
Fry DW, Boritzki TJ, Besserer JA, Jackson RC:In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles). Biochem Pharmacol 34: 3499–3508, 1985
Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of piroxantrone (NSC-349174), a new anthrapyrazole. Cancer Res 50: 3284–3288, 1990
Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL, Rubin J, Moertel CG: Phase I and clinical pharmacological evaluation of piroxantrone hydrochloride (Oxantrazole). Cancer Res 50: 3905–3909, 1990
Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981
Flaherty L, Hussein M, Liu PY, Smith D, Sondak V: Comparison of patient characteristics and outcome between a single institution and cooperative group phase II trial in metastatic melanoma with identical eligibility (abstract). Proc Am Soc Clin Oncol 13: 397, 1994
Zalupski MM, Benedetti J, Balcerzak SP, Hutchins LF, Belt RJ, Hantel A, Goodwin JW: Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas: a Southwest Oncology Group study. Inv New Drugs 11: 337–341, 1993
Slavik M, Kopecky KJ, Sondak V, Craig JB, Samson MK: Evaluation of amonafide in disseminated malignant melanoma: a Southwest Oncology Group study. Inv New Drugs 11: 223–226, 1993
Sondak VK, Kopecky LJ, Liu PY, Fletcher WS, Harvey WH, Roach RW: Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group. Anticancer Drugs 5: 147–150, 1994
Arseneau JC, Schoenfeld DA, Borden EC: A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma. Inv New Drugs 4: 53–56, 1986
Amato DA, Bruckner H, Guerry D, Ash A, Falkson G, Borden EC, Creech RH, Savlov ED, Cunningham TJ: Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. Inv New Drugs 5: 293–297, 1987
Savarese DMF, Denicoff AM, Berg SL, Hillig M, Baker SP, O’Shaughnessy JA, Chow C, Otterson GA, Balis FM, Poplack DG, Cowan KH: Phase I study of high dose piroxantrone with granulocyte colony-stimulating factor. J Clin Oncol 11: 1795–1803, 1993
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sosman, J.A., Flaherty, L.E., Liu, P.Y. et al. A phase II trial of piroxantrone in disseminated malignant melanoma. Invest New Drugs 13, 83–87 (1995). https://doi.org/10.1007/BF02614226
Issue Date:
DOI: https://doi.org/10.1007/BF02614226